查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1932034

伤口护理生技药品市场按产品类型、应用、最终用途和分销管道划分，全球预测（2026-2032年）

Wound Care Biologics Market by Product Type, Application, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，创伤护理生物製药市场价值将达到 16.1 亿美元，到 2026 年将成长至 17.1 亿美元，到 2032 年将达到 26.8 亿美元，复合年增长率为 7.57%。

关键市场统计数据
基准年 2025 16.1亿美元
预计年份：2026年 17.1亿美元
预测年份 2032 26.8亿美元
复合年增长率 (%) 7.57%

生物製药在创伤护理中的应用：创新、病患疗效、临床应用障碍以及医疗保健机构策略机会的综述

在科学进步、临床需求和护理模式转移的推动下，创伤护理领域的生物製药正经历蓬勃发展。再生医学的创新、对修復生物学更深入的理解以及递送平台的改进，共同为临床医生治疗急性伤口、烧烫伤相关伤口和慢性伤口提供了更丰富的治疗工具。同时，医疗系统也要求提供明确的价值证据、高效率的实施途径以及与现有护理通讯协定的整合。

从监管适应症和证据要求到临床路径整合和商业性现代化，识别正在重塑创伤护理生物製药的变革性转变。

近年来，创伤护理生态系统经历了变革性的变化，其影响远不止于产品平臺，还包括监管、商业实践和临床实践等方面的改变。生物製药的进步拓展了治疗选择，法规结构也随之调整，以适应复杂的联合疗法和细胞疗法。同时，临床通讯协定也在不断发展，多学科团队将新型生物製药纳入综合护理路径，旨在缩短创伤治疗时间并降低患者再入院率。

评估2025年美国关税变化对生物製药供应链、定价策略、采购行为和临床进入趋势的累积影响

2025年推出的关税和贸易政策变化对创伤护理生物製药行业有着复杂的影响，涵盖从原材料采购和生产到定价策略和临床准入等各个方面。依赖跨国采购关键原料和生物製药成分的製造商可能面临更高的到岸成本和供应波动，这促使他们寻求供应商多元化并重新评估近岸外包方案。同时，进口关税的提高加剧了先进治疗方法研发过程中固有的成本压力，可能影响临床计画的优先顺序和资金配置。

透过对产品形态、临床应用、终端使用环境和分销管道进行详细的细分市场分析，揭示了不同的市场采纳驱动因素和营运挑战。

细分市场层面的洞察揭示了主要产品类型及其子类别之间截然不同的发展轨迹和临床应用模式。细胞外基质产品因其结构支撑和支架功能而持续受到重视，而生长因子则越来越多地被用于生物目标调控。在众多生长因子中，表皮生长因子、血小板衍生生长因子和转化生长因子β (TGF-β) 等因子具有不同的临床特性和证据要求，这影响了其应用场景的选择。富血小板血浆 (PRP) 已找到一个利基市场，自体血浆疗法可与某些门诊和日间手术相容。同时，干细胞疗法的进展正在推动以可再生和生产扩充性重点的研究活动。此外，皮肤替代物（包括人源、猪源和合成来源）在生物相容性、供应链可靠性和操作便利性之间各有优劣，这影响临床医生根据伤口类型和治疗环境的选择。

区域比较分析显示了监管差异、支付方结构和交付模式如何影响美洲、欧洲、中东和非洲以及亚太地区的医疗服务采用。

区域趋势反映了监管环境、报销模式和医疗服务系统的差异，从而以截然不同的方式塑造了研究、商业化和应用路径。在美洲，创新中心与大规模综合医疗系统并存，这要求提供强有力的疗效比较证据，并促进产学研合作进行临床检验。监管和报销环境鼓励在推广至更广泛的医院系统之前，先在专科中心进行试点，并特别强调产品可追溯性和供应商的真实性。

对创伤护理生物製药市场中决定领先地位的製造能力、临床证据和商业性可行性方面的差异化策略进行竞争分析

创伤护理生技药品领域的竞争格局呈现出全球领先企业、专注于临床阶段的新创公司以及新兴平台技术提供者并存的局面。主要企业透过投资可扩展的生产流程、生技药品製剂製剂和递送技术的智慧财产权，以及涵盖随机试验和真实世界评估的全面证据产生专案来实现差异化竞争。策略联盟、授权和合作伙伴关係是加速临床检验和扩大分销范围的常用手段，而有针对性的收购则有助于整合互补能力并简化上市流程。

整合临床证据、价值链韧性和目标商业化策略以加速生物製剂应用和价值实现的实用建议

产业领导者应优先考虑将科学创新与切实可行的商业化计画结合的策略。首先，投资产生可靠的真实世界证据，以补充随机临床试验，并使终点指标与支付方和医疗服务提供方的优先事项保持一致，从而加快医保覆盖范围的讨论和临床应用。其次，透过多元化的筹资策略、考虑区域性生产方案以及降低贸易中断风险的合约保障措施，增强供应链的韧性。第三，基于市场区隔洞察，建构针对特定临床领域的产品定位。具体而言，针对细胞外基质支架、生长因子製剂、富血小板血浆、皮肤替代物和干细胞疗法等产品，根据伤口类型、治疗环境和医疗服务提供者的能力进行客製化。

我们透明的调查方法结合了与专家的直接对话、二手文献的整合以及严格的检验，以得​​出检验的研究结果和可操作的方案。

这些研究结果背后的研究途径结合了结构化的初步研究、领域专家访谈以及严谨的二手证据审查，以确保分析的深度和实际应用价值。初步研究包括对医院、门诊诊所和专业创伤护理机构的临床医生进行访谈，与生产和供应链负责人进行讨论，以及咨询医保报销专家以了解当前的保险覆盖范围。二手研究整合了监管指南、同行评审的临床文献和公开的临床试验註册信息，以全面整体情况产品的性能、安全性以及不断发展的护理标准。

我们的简要结论强调，临床、商业和营运策略的协调一致将决定哪些生物製药创新将在创伤护理。

这项分析强调，创伤护理生物製药的未来将取决于科学创新、实践证据的产生以及适应性商业化策略的三者交汇融合。细胞外基质、生长因子、富血小板血浆、皮肤替代物和干细胞疗法等领域的技术进步拓展了治疗的可能性，但它们在现实世界中的影响将取决于与临床工作流程、支付方预期和物流实际情况的精准契合。 2025年的关税环境和区域监管机构进一步凸显了建立具有韧性的供应链和製定量身定制的市场推广计划的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型伤口护理生技药品市场

  • 细胞外基质产品
  • 生长因子
    • 表皮生长因子
    • 血小板衍生生长因子
    • 转化生长因子β
  • 富血小板血浆
  • 皮肤替代品
    • 人造皮肤
    • 猪源替代品
    • 合成替代品
  • 干细胞疗法

第九章 按应用分類的伤口护理生技药品市场

  • 急性伤口
    • 外科性创伤
    • 创伤性伤口
  • 烧伤
    • 全层烧伤
    • 局部烧伤
  • 慢性伤口
    • 糖尿病足溃疡
    • 压疮
    • 静脉性腿部溃疡

第十章 以最终用途分類的伤口护理生技药品市场

  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院
    • 住院设施
    • 门诊治疗环境
  • 专业创伤护理中心

第十一章伤口护理生技药品市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 按地区伤口护理生技药品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章伤口护理生技药品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国伤口护理生技药品市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国伤口护理生技药品市场

第十六章：中国伤口护理生技药品市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Aroa Biosurgery
  • Avita Medical
  • B. Braun SE
  • Baxter International Inc.
  • Bioventus Inc.
  • Cardinal Health
  • Celularity Inc.
  • CollPlant Biotechnologies Ltd.
  • Coloplast A/S
  • Convatec Group Plc
  • DeRoyal Industries, Inc.
  • Essity Health & Medical
  • Grifols
  • Hollister Incorporated
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson Services, Inc.
  • Kerecis Ehf.
  • Medline Industries, LP
  • Medtronic PLC
  • MiMedx Group, Inc.
  • Molnlycke Health Care AB
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • Stryker Corporation
Product Code: MRR-7B550E008E37

The Wound Care Biologics Market was valued at USD 1.61 billion in 2025 and is projected to grow to USD 1.71 billion in 2026, with a CAGR of 7.57%, reaching USD 2.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.71 billion
Forecast Year [2032] USD 2.68 billion
CAGR (%) 7.57%

A forward-looking introduction to biologics in wound care that outlines technological innovation, patient outcomes, clinical adoption barriers, and strategic opportunities across care settings

The biologics landscape for wound care is in the midst of dynamic transformation driven by scientific advances, clinical demand, and shifting care paradigms. Innovations in regenerative medicine, refined understanding of repair biology, and improvements in delivery platforms are converging to create a richer therapeutic toolkit for clinicians treating acute, burn-related, and chronic wounds. At the same time, healthcare systems are requiring clearer evidence of value, streamlined pathways to adoption, and integration with existing care protocols.

These pressures and opportunities are reshaping investment priorities across industry, academic, and clinical stakeholders. Where previous decades emphasized single-mechanism interventions, current efforts favor combination approaches and technologies that align with outcome-driven reimbursement models. As a result, product development is increasingly informed by real-world use cases, payer expectations, and the practicalities of clinical workflow, ensuring that new biologic therapies are not only efficacious in controlled settings but also feasible and impactful in everyday care environments.

Identifying the transformative shifts reshaping biologics for wound care, from regulatory adaptation and evidence expectations to clinical pathway integration and commercial modernization

Recent years have witnessed transformative shifts in the wound care ecosystem that extend beyond product pipelines to include regulatory, commercial, and clinical practice changes. Advances in biologic modalities have broadened therapeutic options, while regulatory frameworks are adapting to accommodate complex combination products and cell-based therapies. Concurrently, clinical protocols are evolving as multidisciplinary teams incorporate novel biologics into integrated care pathways designed to reduce healing times and decrease readmission rates.

Commercially, there is a pronounced move toward value-based contracting and outcomes-linked arrangements, which places a premium on robust real-world evidence generation and patient-centered endpoints. Supply chain modernization and digital tools are enhancing product traceability and enabling remote monitoring, which together support broader adoption across ambulatory surgical centers, outpatient clinics, and home care environments. These collective shifts underscore a sector-wide pivot from discrete product launches to ecosystem-level strategies that emphasize longitudinal patient benefit and systemic cost-efficiency.

Assessing the cumulative consequences of 2025 United States tariff changes on biologics supply chains, pricing strategies, procurement behaviors, and clinical access dynamics

The introduction of tariffs and trade policy changes in 2025 has created a complex set of implications for the wound care biologics sector that extend from sourcing and manufacturing to pricing strategy and clinical access. Manufacturers that rely on cross-border procurement of critical raw materials or biologic components face higher landed costs and potential supply variability, prompting reassessments of supplier diversification and nearshoring options. In parallel, increased import duties can accentuate the cost pressures inherent in advanced therapy development, influencing prioritization of clinical programs and capital allocation.

Health systems and providers may experience downstream effects through altered purchasing dynamics and formulary negotiations, particularly for high-cost biologic products with limited domestic manufacturing. Payers, responding to cost inflation, are likely to tighten coverage criteria and emphasize comparative effectiveness data, which elevates the importance of head-to-head studies and robust outcomes measurement. To mitigate these cumulative impacts, stakeholders are refining procurement strategies, accelerating local manufacturing investments where feasible, and enhancing supply chain resilience through contractual hedging and strategic partnerships.

Detailed segmentation analysis connecting product modalities, clinical applications, end-use environments, and distribution channels to reveal differentiated adoption drivers and operational challenges

Segment-level insights reveal distinct development trajectories and clinical adoption patterns across the primary product categories and their subsegments. Extracellular matrix products continue to be valued for structural support and scaffolding capabilities, while growth factors are increasingly positioned for targeted biological modulation; within growth factors, agents such as epidermal growth factor, platelet-derived growth factor, and transforming growth factor beta exhibit divergent clinical profiles and evidence requirements that influence use-case selection. Platelet-rich plasma has found a specific niche where autologous approaches align with certain outpatient and ambulatory procedures, and stem cell therapy advancements are driving investigational activity with an emphasis on regenerative potential and manufacturing scalability. Meanwhile, skin substitutes-available as human-derived, porcine-derived, and synthetic options-offer varying trade-offs between biocompatibility, supply chain reliability, and procedural handling, shaping clinician preference by wound type and care setting.

Application-oriented segmentation highlights varied therapeutic demands that drive product choice and clinical workflow. Acute wounds, including surgical and traumatic wounds, prioritize rapid closure and infection prevention, whereas burn management differentiates between full-thickness and partial-thickness injuries, each requiring tailored biologic approaches and dressing strategies. Chronic wounds such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers demand sustained care pathways, multidisciplinary coordination, and durable evidence of healing and recurrence reduction. End-use segmentation further informs commercialization strategy: ambulatory surgical centers, clinics, home care providers, hospitals in both inpatient and outpatient settings, and specialty wound care centers each present distinct procurement processes, clinical competencies, and reimbursement environments that manufacturers must navigate. Finally, distribution channel segmentation-spanning clinic pharmacies, hospital pharmacies, online pharmacies, and retail pharmacies-adds another layer of operational complexity, influencing inventory models, cold chain logistics, and point-of-care availability.

Comparative regional insights illustrating how regulatory variation, payer structures, and healthcare delivery models in the Americas, Europe Middle East & Africa, and Asia-Pacific influence adoption

Regional dynamics shape research, commercialization, and adoption pathways in markedly different ways, reflecting regulatory regimes, reimbursement models, and healthcare delivery architectures. In the Americas, innovation hubs coexist with large integrated health systems that demand strong evidence of comparative effectiveness, fostering partnerships between industry and academic centers for clinical validation. The regulatory and reimbursement landscape incentivizes pilots in specialized centers before broader hospital system rollout, and there is a pronounced emphasis on product traceability and supplier reliability.

In Europe, Middle East & Africa, heterogeneity in regulatory pathways and payer fragmentation requires nuanced market entry strategies that account for national-level approval processes and variable procurement mechanisms. Capacity constraints in certain healthcare systems can slow uptake, but centralized procurement initiatives and cross-border collaborations create opportunities for scaled rollouts where cost-effective solutions demonstrate clinical benefit. Asia-Pacific markets exhibit a combination of rapid adoption in high-capacity urban centers and emergent demand in decentralized care settings. Manufacturers operating across these regions must tailor clinical evidence packages, pricing strategies, and distribution models to local norms while balancing global manufacturing and regulatory efficiencies. Across all regions, strategic partnerships and adaptive commercialization play pivotal roles in converting clinical promise into real-world impact.

Strategic competitive review describing how differentiated capabilities in manufacturing, clinical evidence, and commercial execution determine market leadership in wound care biologics

Competitive dynamics within the wound care biologics arena are characterized by a mix of global incumbents, specialized clinical-stage developers, and emerging platform technology providers. Leading organizations differentiate through investment in scalable manufacturing, intellectual property around biologic formulations and delivery technologies, and comprehensive evidence generation programs that encompass randomized studies and pragmatic real-world evaluations. Strategic alliances, licensing arrangements, and co-development partnerships are common mechanisms to accelerate clinical validation and broaden distribution reach, while targeted acquisitions serve to consolidate complementary capabilities and streamline go-to-market execution.

Companies that combine regulatory expertise with deep clinical engagement achieve earlier integration into treatment algorithms and formulary discussions. Operational excellence in cold chain management, quality systems, and regulatory compliance further sustains market credibility, particularly for advanced therapies that require specialized handling. Moreover, manufacturers that proactively design health economic analyses and outcomes measurement frameworks are better positioned to navigate evolving reimbursement environments and secure place-in-therapy across diverse care settings. Altogether, success in this sector requires balancing scientific differentiation with pragmatic attention to commercialization execution and stakeholder alignment.

Actionable recommendations for leaders to align clinical evidence, supply chain resilience, and targeted commercialization approaches to accelerate biologics adoption and value realization

Industry leaders should prioritize integrated strategies that align scientific innovation with pragmatic commercialization planning. First, invest in robust real-world evidence generation that complements randomized clinical trials and maps endpoints to payer and provider priorities, thereby accelerating coverage discussions and clinical uptake. Second, strengthen supply chain resilience through multiple sourcing strategies, consideration of regional manufacturing options, and contractual protections that reduce vulnerability to trade disruptions. Third, tailor product positioning to specific clinical niches informed by segmentation insights-matching extracellular matrix scaffolds, growth factor agents, platelet-rich plasma, skin substitutes, and stem cell approaches to wound type, care setting, and provider capability.

In addition, organizations should pursue targeted partnerships with specialty wound centers and integrated health systems to refine care pathways and demonstrate value at the point of care. Investing in clinician training, handling protocols, and patient education materials will support adoption and optimize outcomes. Finally, develop flexible pricing and contracting models that reflect outcome-based arrangements where appropriate, while building robust health economic dossiers to support negotiations with payers and procurement entities. By combining clinical rigor with operational dexterity, leaders can translate biologic innovation into sustainable clinical and commercial impact.

Transparent research methodology combining expert primary engagements, secondary literature synthesis, and rigorous triangulation to produce validated insights and actionable scenarios

The research approach underpinning these insights combined structured primary engagements with subject-matter experts and a rigorous secondary evidence review to ensure analytical depth and practical relevance. Primary inputs included interviews with clinicians across hospital, outpatient, and specialty wound care settings, discussions with manufacturing and supply chain leaders, and consultations with reimbursement specialists to capture contemporary coverage considerations. Secondary research synthesized regulatory guidance, peer-reviewed clinical literature, and publicly available clinical trial registries to construct a comprehensive picture of product performance, safety profiles, and evolving standards of care.

Analytical rigor was ensured through data triangulation across sources, iterative validation with clinical and commercial experts, and thematic synthesis to identify cross-cutting trends and region-specific nuances. Quality control processes included cross-referencing regulatory documents and product labeling, assessing methodological quality of clinical studies, and stress-testing strategic implications against plausible operational scenarios. Where appropriate, the methodology incorporated scenario analysis to explore alternative outcomes under varying supply chain, policy, and reimbursement conditions, enabling stakeholders to plan for a range of contingencies while preserving the integrity of core findings.

A concise conclusion emphasizing how coordinated clinical, commercial, and operational strategies will determine which biologic innovations achieve sustained impact in wound care

This analysis underscores that the future of wound care biologics is defined by the intersection of scientific innovation, pragmatic evidence generation, and adaptive commercialization strategies. Technological strides in extracellular matrices, growth factors, platelet-rich plasma, skin substitutes, and stem cell therapies expand therapeutic possibilities, but their real-world impact depends on thoughtful alignment with clinical workflows, payer expectations, and logistical realities. The 2025 tariff landscape and regional regulatory heterogeneity further emphasize the need for resilient supply chains and tailored market-entry plans.

Moving forward, stakeholders who combine clinical excellence with disciplined operational execution will capture disproportionate value. That requires early and continuous collaboration with clinicians and payers, investment in real-world outcome measurement, and flexible commercial constructs that reflect differentiated value propositions across acute, burn, and chronic wound indications. By pursuing these strategic imperatives, developers and providers can accelerate translation from laboratory promise to measurable improvements in patient care and system-level efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Wound Care Biologics Market, by Product Type

  • 8.1. Extracellular Matrix Products
  • 8.2. Growth Factors
    • 8.2.1. Epidermal Growth Factor
    • 8.2.2. Platelet-Derived Growth Factor
    • 8.2.3. Transforming Growth Factor Beta
  • 8.3. Platelet-Rich Plasma
  • 8.4. Skin Substitutes
    • 8.4.1. Human Skin Substitutes
    • 8.4.2. Porcine-Derived Substitutes
    • 8.4.3. Synthetic Substitutes
  • 8.5. Stem Cell Therapy

9. Wound Care Biologics Market, by Application

  • 9.1. Acute Wounds
    • 9.1.1. Surgical Wounds
    • 9.1.2. Traumatic Wounds
  • 9.2. Burns
    • 9.2.1. Full-Thickness Burns
    • 9.2.2. Partial-Thickness Burns
  • 9.3. Chronic Wounds
    • 9.3.1. Diabetic Foot Ulcers
    • 9.3.2. Pressure Ulcers
    • 9.3.3. Venous Leg Ulcers

10. Wound Care Biologics Market, by End Use

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals
    • 10.4.1. Inpatient Settings
    • 10.4.2. Outpatient Settings
  • 10.5. Specialty Wound Care Centers

11. Wound Care Biologics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Wound Care Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Wound Care Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Wound Care Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Wound Care Biologics Market

16. China Wound Care Biologics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. Aroa Biosurgery
  • 17.7. Avita Medical
  • 17.8. B. Braun SE
  • 17.9. Baxter International Inc.
  • 17.10. Bioventus Inc.
  • 17.11. Cardinal Health
  • 17.12. Celularity Inc.
  • 17.13. CollPlant Biotechnologies Ltd.
  • 17.14. Coloplast A/S
  • 17.15. Convatec Group Plc
  • 17.16. DeRoyal Industries, Inc.
  • 17.17. Essity Health & Medical
  • 17.18. Grifols
  • 17.19. Hollister Incorporated
  • 17.20. Integra LifeSciences Holdings Corporation
  • 17.21. Johnson & Johnson Services, Inc.
  • 17.22. Kerecis Ehf.
  • 17.23. Medline Industries, LP
  • 17.24. Medtronic PLC
  • 17.25. MiMedx Group, Inc.
  • 17.26. Molnlycke Health Care AB
  • 17.27. Organogenesis Holdings Inc.
  • 17.28. Smith & Nephew Plc
  • 17.29. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL WOUND CARE BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EXTRACELLULAR MATRIX PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EXTRACELLULAR MATRIX PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EXTRACELLULAR MATRIX PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-DERIVED GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-DERIVED GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-DERIVED GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRANSFORMING GROWTH FACTOR BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRANSFORMING GROWTH FACTOR BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRANSFORMING GROWTH FACTOR BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HUMAN SKIN SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HUMAN SKIN SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HUMAN SKIN SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PORCINE-DERIVED SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PORCINE-DERIVED SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PORCINE-DERIVED SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SYNTHETIC SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SYNTHETIC SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SYNTHETIC SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRAUMATIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRAUMATIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY TRAUMATIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY FULL-THICKNESS BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY FULL-THICKNESS BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY FULL-THICKNESS BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PARTIAL-THICKNESS BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PARTIAL-THICKNESS BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PARTIAL-THICKNESS BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PRESSURE ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PRESSURE ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY PRESSURE ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY INPATIENT SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY INPATIENT SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY INPATIENT SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY OUTPATIENT SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY OUTPATIENT SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY OUTPATIENT SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SPECIALTY WOUND CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SPECIALTY WOUND CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY SPECIALTY WOUND CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 210. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 254. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOUND CARE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA WOUND CARE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA WOUND CARE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)